TuHURA Biosciences Inc (HURA) - Total Assets
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) holds total assets worth $31.75 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TuHURA Biosciences Inc - Total Assets Trend (2014–2026)
This chart illustrates how TuHURA Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see HURA market cap overview for the company's overall valuation and market capitalisation.
TuHURA Biosciences Inc - Asset Composition Analysis
Current Asset Composition (June 2026)
TuHURA Biosciences Inc's total assets of $31.75 Million consist of 16.9% current assets and 83.1% non-current assets. Review total liabilities of TuHURA Biosciences Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.28 Million | 41.2% |
| Goodwill | $10.74 Million | 39.3% |
Asset Composition Trend (2014–2026)
This chart illustrates how TuHURA Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest TuHURA Biosciences Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TuHURA Biosciences Inc's current assets represent 16.9% of total assets in 2026, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 13.2% of total assets in 2026, down from 95.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 80.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 41.2% of total assets.
TuHURA Biosciences Inc Competitors by Total Assets
Key competitors of TuHURA Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
TuHURA Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.18 | 0.83 | 6.70 |
| Quick Ratio | 0.18 | 0.83 | 6.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-7.60 Million | $-2.63 Million | $17.11 Million |
TuHURA Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between TuHURA Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.41 |
| Latest Market Cap to Assets Ratio | 4.68 |
| Asset Growth Rate (YoY) | 37.0% |
| Total Assets | $27.35 Million |
| Market Capitalization | $128.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TuHURA Biosciences Inc's assets at a significant premium (4.68x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: TuHURA Biosciences Inc's assets grew by 37.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TuHURA Biosciences Inc (2014–2026)
The table below shows the annual total assets of TuHURA Biosciences Inc from 2014 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $27.35 Million | +36.99% |
| 2025-06-30 | $19.97 Million | +357.76% |
| 2024-06-30 | $4.36 Million | -71.30% |
| 2023-06-30 | $15.20 Million | +137.36% |
| 2022-06-30 | $6.40 Million | -52.73% |
| 2021-06-30 | $13.54 Million | +360.96% |
| 2020-06-30 | $2.94 Million | -27.23% |
| 2019-06-30 | $4.04 Million | -42.94% |
| 2018-06-30 | $7.07 Million | -10.57% |
| 2017-06-30 | $7.91 Million | +24.47% |
| 2016-06-30 | $6.36 Million | +146.79% |
| 2015-06-30 | $2.58 Million | -40.37% |
| 2014-06-30 | $4.32 Million | -- |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more